

1 *Review*2 **New challenges in (bio)analytical sample treatment procedures**
3 **for clinical applications**4 Valentina Greco¹, Marcello Locatelli^{2,*}, Fabio Savini³, Ugo de Grazia⁴, Ottavia Montanaro², Enrica Rosato²,
5 Miryam Perrucci², Luigi Ciriolo², Abuzar Kabir⁵, Halil Ibrahim Ulusoy⁶, Cristian D'Ovidio⁷, Imran Ali⁸,
6 Alessandro Giuffrida¹7 ¹Department of Chemical Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy; [ales-](mailto:alesandro.giuffrida@unict.it)
8 sandro.giuffrida@unict.it (A.G.), valentina.greco@unict.it (V.G.)9 ²Department of Pharmacy, University of Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, 66100 Chieti, Ita-
10 ly; marcello.locatelli@unich.it (M.L.), ottavia.montanaro@studenti.unich.it (O.M.), enrica.rosato@unich.it
11 (E.R.), miryamper97@gmail.com (M.P.), ciriololuigi123@gmail.com (L.C.)12 ³Pharmatotoxicology Laboratory—Hospital "Santo Spirito", Via Fonte Romana 8, 65124 Pescara, Italy; [fa-](mailto:fabio.savini@ausl.pe.it)
13 bio.savini@ausl.pe.it (F.S.)14 ⁴Laboratory of Neurological Biochemistry and Neuropharmacology, Fondazione IRCCS Istituto Neurologico
15 Carlo Besta, Via Celoria 11, 20133 Milano, Italy; Ugo.DeGrazia@istituto-besta.it (U.d.G.)16 ⁵Department of Chemistry and Biochemistry, International Forensic Research Institute, Florida International
17 University, Miami, FL 33199, USA; akabir@fiu.edu (A.K.)18 ⁶Department of Analytical Chemistry, Faculty of Pharmacy, Cumhuriyet University, Sivas 58140, Turkey; [lulusoy@yahoo.com](mailto:hiu-
19 <a href=) (H.I.U.)20 ⁷Section of Legal Medicine, Department of Medicine and Aging Sciences, University of Chieti-Pescara "G.
21 d'Annunzio", 66100 Chieti, Italy; crislian.dovidio@unich.it (C.D.O.)22 ⁸Department of Chemistry, Jamia Millia Islamia (Central University), Jamia Nagar, New Delhi, 110025, India;
23 drimran_ali@yahoo.com (I.A.)24 * Correspondence: marcello.locatelli@unich.it
2526 **Abstract:** The primary cause of poor and ambiguous results obtained from bioanalytical
27 process is the sample pre-treatment, especially in clinical analysis, e.g., because it in-
28 volves dealing with complex sample matrices, such as whole blood, urine, saliva, serum
29 and plasma. So, the aim of this review is to focus the attention on classical and new
30 techniques of pre-treatment for biological samples used in the bioanalytical process. We
31 discussed the methods generally used for these types of complex samples. Undoubtedly,
32 it is a daunting task to deal with biological samples because the analyst may encounter
33 substantial loss of the analytes of interest, or the overall analysis may be too much time
34 consuming. Nowadays, we are inclined to use green solvents for the environment, but
35 without sacrificing the analytical performance and selectivity. All the characteristics
36 mentioned above should be added to the difficulty of withdrawal of samples like blood,
37 because it can be an invasive practice. For these reasons, now we can also find in the lit-
38 erature, the use of saliva as an alternative biological sample and new techniques that
39 don't require substantial sample pre-treatment such as fabric phase sorptive extraction
40 (FPSE). The text has been divided into two distinct parts: in the first one, we described
41 clinical applications under different subsections such as anticancer drugs, antibiotics,
42 vitamins, antivirals, non-steroidal anti-inflammatory drugs, statin, imidazoles and tria-
43 zoles. The second part is dedicated to sample preparation techniques for diagnostic
44 purposes and is divided into different sample preparation techniques: solid phase mi-
45 croextraction (SPME), Microextraction by packed sorbent (MEPS), Dispersive liq-
46 uid-liquid microextraction (DDLME), and Fabric Phase Sorptive Extraction (FPSE).47 **Keywords:** clinical analytical chemistry; drug analysis; sample treatment; Green analytical chem-
48 istry30 **Citation:** To be added by editorial
31 staff during production.32 Academic Editor: Firstname Last-
33 name

34 Received: date

35 Accepted: date

36 Published: date

37 **Publisher's Note:** MDPI stays neu-
38 tral with regard to jurisdictional
39 claims in published maps and insti-
40 tutional affiliations.41 **Copyright:** © 2022 by the authors.

42 Submitted for possible open access

43 publication under the terms and

44 conditions of the Creative Commons

45 Attribution (CC BY) license

46 (<https://creativecommons.org/licenses/by/4.0/>).

47

49

50

1. Introduction

51

The analysis of biological samples requires an adequate sample preparation procedure that has an inevitable role in the analytical process. In fact, the sample preparation step may influence the accuracy of results, and it consumes most of the time needed for the overall analytical workflow.

52

53

54

55

56

57

58

59

60

61

The traditional methods applied in many fields including bioanalysis, such as solid-phase extraction (SPE) and liquid-liquid extraction (LLE), have shown some limitations due to their use of toxic organic solvents and long processing time. Therefore, new methods based on microextraction techniques have been developed to achieve high recovery of target analytes from simple to complex sample matrices, and to comply with the concepts of the Green Chemistry (GC) and Green Analytical Chemistry (GAC). [1]

62

63

64

Biological samples include whole blood, plasma, serum, urine, feces, saliva, bile, hair, sweat, breast milk, cerebrospinal fluid (CSF), tissues, and bio analytes (DNA, defined proteins, drugs and specific metabolites or unknown molecules).

65

66

67

68

69

70

The stability of these samples is important, often they are rich in endogenous components such as carbohydrates, proteins, lipids, and salts that can interfere with the targets search due to matrix effects. Moreover, analytes are often present at very low concentration and for this reason the target analytes need to be preconcentrated prior to analysis that often enhance the levels of interfering molecules (e.g., drugs, salts and metabolites, nucleic acids, proteins, and peptides). [2]

71

72

73

74

75

76

77

78

79

80

After collection from patients and appropriate storage, the sample clean up and preparation step becomes crucial to avoid damage also caused by endogenous degrading properties (enzymes activities, cell death, etc.) and to perform an accurate and selective bioanalysis to obtain a real and correct “picture” of the studied system. [3]

81

82

83

84

85

These sample preparation techniques include liquid phase microextraction (LPME) with its different modifications such as single-drop microextraction (SDME), dispersive liquid-liquid microextraction (DLLME), hollow fiber liquid-phase microextraction (HF-LPME) and solidified floating organic drop microextraction (SFO-DME). In LPME, the extraction phase is based on the action of different solvents (e.g., DESs, ILs, and ferrofluids) that with its features and properties play an important role for the entire process (in terms of recovery, enrichment factor, selectivity).

86

87

88

89

90

91

Other techniques include solid phase microextraction (SPME), microextraction by packed sorbent (MEPS), and fabric phase sorptive extraction (FPSE). [4,5] These techniques manifest a rapid development in different fields, such as biological, environmental, food sciences, natural products, forensic medicine, and toxicology [1].

92

The clinical applications of (bio)analytical sample treatment procedures are very extensive in different fields, ranging from the search for biomarkers useful in the diagnosis of many diseases to those necessary for personalized therapeutic drug monitoring (TDM).

93

94

2. Clinical applications

95

2.1 Anticancer drugs

96

97

Zufía, Aldaz, and Giráldez (2004) reported the use of a mixture of ethyl acetate and acetonitrile (4:1, *v/v*) after sample acidification with orthophosphoric acid to simultaneously extract capecitabine, 5'-DFUR (5'-deoxy- 5-fluorouridine), 5-FU (5-fluorouracil), and 5-FUH2 (5,6-dihydro-5-fluorouracil) from plasma. Similar extraction method is also

reported using LLE with a mixture of ethyl acetate and acetonitrile as the extractant (8:3, *v/v*). [6]

Piórkowska et al. (2014) have reported a similar extraction method using a mixture of ethyl acetate and acetonitrile (4:1, *v/v*) but without sample acidification. Acidification was not deemed necessary because the assay was developed to determine only Capecitabine concentrations (no metabolites). [6]

Table 1. Pre-treatment of biological samples for Capecitabine and its metabolites

Analyte	Sample	Treatment	LOD/LOQ	Ref.
Capecitabine	Human plasma	LLE	LOQ: 0.025ug/mL	[7]
5'-DFUR				
5-FU			LOD: 0.01ug/mL	
5-FUH2				
Capecitabine	Human plasma	LLE	CC: 0.05/10 ug/mL	[8]
Capecitabine	Human plasma	LLE	LLQ: 1.00/10.00 ng/mL	[9]
5-FU		LLE		
FBAL		LLE + SPE		
Capecitabine	Human plasma	SPE	LOD: 0.007(Capecitabine)	[10]
5'-DFCR			0.08 (5-DFUR)	
5'-DFUR			0.6 (5-DFCR)	
5-FU			0.08 (5-FU) ng/mL	
			LOQ: 0.02 (Capecitabine)	
	0.3 (5-DFUR)			
	2 (5-DFCR)			
	0.3 (5-FU) ng/mL			
Capecitabine	Human plasma	SPE	LOD: 39 ng	[11]
			LOQ: 156 ng	
Capecitabine	Human plasma	SPE	LOQ: 156 ng/mL	[12]
			LOD: 78 ng/mL	
Capecitabine	Human plasma	Online SPE	LOQ	[13]
5'-DFCR			1.4 ng/mL (Capecitabine)	
5'-DFUR			17.6 ng/mL (5-DFCR)	
			8.4 ng/mL (5-DFUR)	
Capecitabine	Human plasma	PP	LOQ:	[14]
5'-DFCR			10.0 (Capecitabine)	
5'-DFUR			10.0 (DFCR)	
5-FU			10.0 (DFUR)	
			2.0 (5-FU)	
Capecitabine	Human serum	PP	LOQ: 1 ug/mL	[15]
Capecitabine	Plasma	PP	LOQ ng/mL	[16]
5'-DFCR	Tumor tissue liver		Plasma:	
5'-DFUR			4.0(Capecitabine)	
5-FU			1.4 (DFCR)	
			3.3 (DFUR)	
			45.8 (5-FU)	
			Tumor tissue:	
			1.3 Capecitabine	

			1.7 DFCR 0.5 DFUR 50.0 5-FU	
			Liver: 13.0 Capecitabine 3.0 DFCR 92.0 5-FU	
			No interference DFUR LOQ: 1 ug/mL	[17]
Capecitabine 5'-DFCR 5'-DFUR 5-FU 5-FUH2	Human plasma	PP		
Capecitabine 5'-DFCR 5'-DFUR 5-FU 5-FUH2	Human plasma	LLE	LOQ: 20.0 ng/mL	[18]
FBAL 5'-DFCR 5'-DFUR 5-FU 5-FUH2 FUPA FBAL	Human plasma	PP	LOQ: 50.0 ng/mL	[19]

Cap: Capecitabina; 5'-DFUR: 5'-deoxy- 5-fluorouridine; 5-FU: 5-fluorouracil; 5-FUH2: 5,6-dihydro-5-fluorouracil; 5-DFCR: 5'-deoxy-5- fluorocytidine; FBAL: α -fluoro- β -alanine; FUPA: α -fluoro- β -ureidopropionic acid; LLE: liquid-liquid extraction; PP: protein precipitation; SPE: solid phase extraction

Zufía, Aldaz, and Giráldez [7] used LLE, specifically using a mixture of ethyl acetate and acetonitrile (4:1, *v/v*) after acidification of samples to extract Capecitabine, 5'-dFUR, 5-FU and 5-FUH2 from human plasma. Piórkowska et al. [8] reported a similar LLE method using a mixture of ethyl acetate and acetonitrile (4:1, *v/v*), but without sample acidification, because they wanted to find only Capecitabine and not its metabolites.

Many studies reported the use of protein precipitation like sample treatment for bioanalytical analysis. Deng et al. [14] and Thorat et al. [15] used methanol as the solvent to precipitate the proteins from human plasma and human serum. Furthermore, Vainchtein et al. [17] with the aim of not losing the drug, they added 10% *v/v* of trichloroacetic acid in water.

Another protocol used to extract anticancer drug, specifically Osimertinib, involved LLE. Fresnai et al. used tert-butyl methyl ether for simultaneous extraction and concentration of it. This method was developed to follow treatment for patients with non-small cell lung carcinoma with epidermal growth factor receptor activating mutation. [20]

Llopis et al. studied nine kinase inhibitors including cobimetinib, dasatinib, ibrutinib, imatinib, nilotinib, palbociclib, ruxolitinib, sorafenib and vemurafenib; two active metabolites of them: N-desmethyl imatinib, N-oxide sorafenib; and two Anti Androgen drugs: abiraterone and enzalutamide. They used a single step protein precipitation with 100 μ L of aqueous Zinc Sulfate Monohydrate $ZnSO_4 \cdot H_2O$ (10% *w/v* pH 5.4), adding this to 50 μ L of human plasma followed by vortexing and centrifugation. [21]

Locatelli et al. used whole blood, saliva, and urine samples. The difficulty, especially for whole blood, was to minimize the matrix interferents that can mess up the analysis. Usually, the first step is protein precipitation to convert whole blood into

106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132

133 plasma. In this case, the authors used directly whole blood without converting into
134 plasma, thanks to the extraction protocol using Fabric Phase Sorptive Extraction (FPSE)
135 to avoid the possible loss of analytical information related to the quantification of anas-
136 trozole, letrozole and exemestane used in treatment of metastatic breast cancer. [22]

137 2.2. Antibiotics

138 Ferrari et al. wanted to highlight the matter of a personal treatment of bacterial in-
139 fections, because different people may respond to the drugs in different ways. So, they
140 followed pharmacokinetics studies on Piperacillin, Meropenem, Linezolid and
141 Teicoplanin in plasma samples from patients treated with the mentioned antibiotics.
142 Pre-treatment involved a liquid-liquid extraction, vortexing for 10 seconds and addition
143 of a precipitation buffer, and then vortexing followed by centrifugation. The supernatant
144 was mixed with a dilution buffer and finally analyzed. [23]

145 Wongchang et al. performed their sample preparation through protein precipita-
146 tion. Plasma samples were aliquoted, and they added acetonitrile with cefotaxime as in-
147 ternal standard. The samples were mixed and centrifuged. After this, the supernatant
148 was loaded on Phree phospholipid removal plate and vacuum was applied. Finally, the
149 samples were diluted, mixed and centrifuged. [24]

150 Krnac et al. used human plasma as the sample for their analysis. The aim of this
151 study was to monitor tazobactam, piperacillin and meropenem in patients treated in in-
152 tensive care unit. The authors used a mixture of methanol-acetonitrile-water (6:2:2,
153 v/v/v), specifically 200 uL for 10 uL of human plasma plus 10 uL of internal standard, to
154 precipitate proteins. After mixing, the samples were centrifuged, and the supernatant
155 was used for the analyses. [25]

156 2.3 Vitamin

157 Rola et al. used LLE to find concentration of vitamin D and its metabolites in serum.
158 In the beginning of the procedure, the authors applied LLE followed by PP, but due to
159 low recovery of 24,25-dihydroxyvitamin D₃ (24,25(OH)₂ D₃), they opted for only PP in
160 two different steps: the first one for releasing the compound bound to the protein and
161 the second step is to precipitate most proteins possible. In this case, the organic solvent
162 was acetonitrile. [26]

163 Also, Hotta et al. used PP to understand pharmacokinetic profile of methylco-
164 balamina, which is important in reaction of Vitamin B12. In this case, the authors used
165 methanol as protein precipitation solvent, because the extraction of methylcobalamina
166 was higher with methanol than with acetonitrile. [27]

167 2.4 Antiviral

168 Present HIV therapy appreciates the use of combination of different drugs, like do-
169 lutegravir, elvitegravir, raltegravir, nevirapine and etravirine. Bollen et al. studied the
170 therapeutic drug monitoring of these antiretroviral drugs to analyze the pharmacokinet-
171 ics trials. The authors used plasma samples that pretreat with PP and used the superna-
172 tant as liquid to analyze. [28]

173 Elkady et al. analyzed the treatment of hepatitis C viral infection. Specifically, the
174 combination therapy of sofosbuvir and velpatasvir was found success in the treatment.
175 They used human plasma, which was pretreated with acetonitrile, then vortexed and fi-
176 nally centrifuged. [29]

177 2.5 Non-steroidal anti-inflammatory drugs (NSAIDs)

178 Raabova et al. used human serum taken from patients that were under treatment of
179 intravenous infusion with 75 mg of sodium diclofenac. Blood samples were diluted 10
180 times with 20% aqueous acetonitrile, centrifuged, and the supernatant was analyzed.
181 [30]

182 Kabir et al. in 2018 have focused attention on the analysis on inflammatory bowel
183 disease (IBD). Among different treatment regimens used in IBD, therapeutic interven-
184 tion by oral administration of cortisone, ciprofloxacin and/or sulfasalazine among others
185 are common practices. As such, the authors used a combination of cortisone, ciprofloxacin,
186 and sulfasalazine as an oral treatment regimen. For pharmacokinetic studies, the
187 authors used physiological samples like plasma, serum, saliva, and urine. The whole
188 blood was diluted with ultrapure water (1:5, *v/v*) and vortexed. Human plasma was directly
189 vortexed after adding internal standard and the same protocol was used for urine.
190 Finally, samples were ready to FPSE procedure to analyze the supernatant. [31]

191 Tartaglia et al. analyzed saliva samples from healthy volunteers in absence of
192 NSAIDs, with the aim of analyzing furprofen, indoprofen, ketoprofen, fenbufen, flurbi-
193 profen, and ibuprofen in the above samples. Thanks to FPSE, the authors did not need
194 any pre-treatment, only the addition of the internal standard. [32]

195 D'angelo et al. developed an analytical method based on MEPS and HPLC to quan-
196 tify simultaneously FANS and Fluoroquinolones. They collected plasma and urine sam-
197 ples from healthy volunteers after 5 h after oral administration of FANS and FLQ. The
198 addition of trichloroacetic acid aimed the denaturation of proteins, and after a centri-
199 fuge step, the supernatant was used for the MEPS extraction. [33]

200 2.6 Statin

201 Courlet et al. discussed the risk of cardiovascular events in HIV patients. Atorvas-
202 tatin, rosuvastatin, and pravastatin are the most prescribed lipid-lowering agents in this
203 class of patients. In their study, blood samples from different patients for pharmaco-
204 kinetics studies were collected. Pre-treatment of these samples was protein precipitation.
205 Following centrifugation, the supernatant was then evaporated until dryness and then
206 reconstituted in methanol: H₂O with 0.1% formic acid, vortexed, sonicated, and centri-
207 fuge. Finally, the supernatant was ready to be analyzed. [34]

209 2.7 Imidazoles and triazoles

210 Campestre et al. studied imidazole as Ketoconazole, Bifonazole, Clotrimazole, Tio-
211 conazole, Econazole, Butoconazole and Miconazole and Triazole as Terconazole,
212 Voriconazole, Posaconazole, Ravuconazole and Itraconazole. Specifically, the research
213 group was interested about quantification ofazole derivatives in human samples collected
214 from healthy volunteers (plasma and urine). The samples were mixed with the working
215 analyte solution as well as internal standard and vortexed. With the aim of denaturing
216 proteins and reducing sample density, the samples were pre-treated with trichloroacetic
217 acid and centrifuged, then the supernatant was directly analyzed. [35]


218 The aim of this study was to simplify the clean-up procedures that precede the
219 analysis in HPLC. These authors used plasma and urine samples from healthy volun-
220 teers, added analyte working solutions and internal standard to them and applied ex-
221 traction procedure with FPSE membranes and then analyzed the supernatant in HPLC.
222 [36]

224 3. Recent sample preparation techniques for clinical purposes

225 Particular attention is paid to novel extraction techniques, which significantly reduced
226 the number of operations to be carried out during sample preparation. The aim was to
227 develop extraction devices and technologies easily for operators to reduce time and
228 minimize errors during operations. [37]

230

231

Fig.1 Sources of error generated during chromatographic analysis.

232

233

3.1 Solid Phase Microextraction (SPME)

234

Biological samples contain a variety of metabolites that can be used for clinical purposes in the diagnosis of various clinical conditions and many severe disorders.

235

236

Among sample preparation techniques, the most widely used procedure is solid phase microextraction (SPME) that includes sampling, extraction, and analyte pre-concentration into a single step. By contact with liquid bio-matrices, analytes are transferred to the adsorbent-coated solid surface thanks to the affinity of analytes to the coating material.

237

238

239

240

241

242

243

244

245

246

247

The direct immersion SPME (DI-SPME) and the headspace SPME (HS-SPME) are two modes of SPME operations. The first extraction technique is based on the sorption of analytes on the stationary phase immobilized on a fused silica glass rod that acts as the solid support. During the analyte's extraction, the coated fiber is directly immersed into the sample solution, while in the HS-SPME, the fiber is exposed in the vapor phase above the sample. At equilibrium, the quantity of analyte extracted by the fiber is proportional to its concentration in the sample. [38]

248

249

250

251

252

The main advantages of this methods include simplicity and speed of operations, high sensitivity, and the volume of solvent reduction, for these reasons it has been applied to the investigation of metabolites and neurotransmitters for diagnostic purposes. [39]

253

254

255

256

Many metabolites and neurotransmitters are useful for the diagnosis of neurological diseases. Neurotransmitters (NTs) are basic signaling molecules used for cells communications; they are involved in stress response mechanisms, in the regulation of motor coordination, in the control of psychomotor, gastrointestinal, and homeostatic function and neuronal communication.

257

258

259

260

Many psychomotor, psychiatric, neurodegenerative, and oncological disorders are characterized by an abnormal production, release and/or metabolism of NTs, for this reason NTs can be used as a potential biomarker for diagnoses of Alzheimer's and Parkinson's diseases, neuroendocrine cancers and psychiatric illness such as schizophrenia.

261 The most common biological fluids in NT analysis are urine and blood, but other
262 alternative matrices include CSF and cerebral tissue, with the related difficulty due to
263 the presence of interfering molecules and low levels of the target analytes. Therefore, the
264 development of validated methods of sample preparation and analytical techniques for
265 the quantitative analysis of NT in biological samples is needed. [40]

266 Naccaro et al. developed a method for the determination of NTs such as dopamine
267 (DOP), norepinephrine (NE) and serotonin (5-HT) in human urine by SPME coupled
268 with Gas Chromatography-Triple Quadrupole Mass Spectrometry (GC-QqQ-MS).

269 The optimized SPME method provides a first step of extraction with polyacrylate
270 fiber at room temperature for 45 min without addition of NaCl, the second step was de-
271 sorption at 300 °C, followed by derivatization reaction carried out directly in urine sam-
272 ple and SPME extraction in immersion mode in the same vial (without organic solvent
273 or further sample treatment).

274 The developed method has shown good linearity with correlation coefficient values
275 of 0.9995 for DOP, 0.9999 for 5-HT and 0.9987 for NE; the accuracy values were between
276 92.8 % and 103.0 % and RSD% ranged between 0.67 % and 4.5 %. LOD values was 0.587
277 µg/L for DOP, 0.381 µg/L for 5-HT and 13.5 µg/L for NE and LOQ values was 0.81 µg/L
278 for DOP, 0.74 µg/L for 5-HT and 21.3 µg/L for NE.

279 The obtained satisfactory results indicate that the proposed method can be adapted
280 for analysis of urine samples, which contain much lower concentration of DOP, 5-HT
281 and NE than those determined for healthy adults. Thanks to the rapidity and simplicity
282 of this SPME method with the advantages of minimal sample handling and high sensi-
283 tivity, this procedure might be considered as valuable tool for diagnosis of cancerous
284 and neurological diseases correlated with urinary levels of analyzed amines. [41]

285 Among the markers proposed for the diagnosis of oncological diseases, the scien-
286 tific literature proposes the analysis of volatile organic compounds (VOCs) as a valid al-
287 ternative, due to their importance on identification and differentiation of cancer samples.
288 In particular, the determination of urinary VOCs has been proposed as alternative can-
289 cer biomarkers for lung, bladder, and breast cancer.

290 Monteiro et al. validated a new HS-SPME method to obtain a urine volatile metab-
291 olomics profile useful for renal cell carcinoma (RCC). These compounds generally re-
292 quire a high efficiency of extraction that depends on the sample preparation method se-
293 lected.

294 In this study, the authors validated a HS-SPME method after the optimization of
295 different factors that may influence the results, such as pH of urine sample, fiber coating,
296 time of incubation, and time and temperature of extraction. They tested different condi-
297 tions (3 pH levels, time and temperatures of extraction, temperature of incubation) and
298 fibers (5 types of SPME fibers), amongst these the best results were obtained with the
299 exposition of 2 mL of urine sample with optimal pH 2.0.

300 The use of an acidic pH value confirmed a better HS-SPME extraction in terms of
301 the total of compounds and total chromatographic peak area, but strong acidic condi-
302 tions may determine some error due to chemical degradation of some pH-sensitive
303 compounds.

304 Moreover, the fiber with highest and better performance for urinary volatile metab-
305 olites was divinylbenzene/polydimethylsiloxane (DVB/PDMS). The optimal analytical
306 performance was obtained also with addition of 0.59 g of NaCl, 9 min of incubation and
307 extraction at 68 °C in 24 min.

308 This method was simple, solvent-free, inexpensive, fast with combination of extrac-
309 tion, and preconcentration of sample with minimal pre-treatment. [42]

310 Deeva et al. validated an SPME method to obtain preconcentration of VOCs in
311 urine sample of patients with prostate cancer already confirmed by prostatic puncture
312 biopsy, for subsequent non-target GC-MS analysis.

313 In this procedure, 3 mL of urine with 0.3 g of sodium chloride was placed inside the
314 headspace vial, the extraction equilibrium was obtained with stirring (250 rpm) on the

315 hotplate. 100- μm -thick polydimethylsiloxane fibers were used for SPME, these fibers
316 were treated at 250° C for 15 minutes to remove impurities before sample analysis. The
317 fibers were placed in the headspace above the urine samples for 20 minutes at 50 °C, and
318 then were inserted into the hot GC injector with the adsorbed analytes, which were de-
319 sorbed for 4 min in splitless modes. After this procedure, the samples were analyzed
320 with GC-MS. This method showed a very high sensitivity, specificity, and accuracy, and
321 might be a good approach in non-invasive prostate cancer screening. [43]

322 Blood steroid levels are often required for the diagnosis of various endocrinological
323 diseases involving the pituitary-adrenal axis, such as hypercortisolism and Cushing's
324 syndrome. In addition to blood, saliva also represents a biological sample of considera-
325 ble interest for diagnostic purposes, due to the presence of these hormones in free form
326 with concentration correlated to that present in the blood. Often the saliva concentration
327 of endogenous steroids is very low, and it is necessary to employ a highly sensitive ana-
328 lytical technique.

329 Bessoneau et al. validated a method for the quantification of endogenous steroids
330 (cortisol, testosterone, and progesterone, E1, E2 and E3) in saliva with *in vivo* SPME. The
331 extraction method was developed using biocompatible coated SPME blades that were
332 first conditioned for 30 min with 1.5 mL of methanol/water (50:50, *v: v*) in 96-well-plates
333 with agitation; all analytes required a time of 60 min for equilibrium extraction. To
334 guarantee a complete immersion of the coating in the sample and to improve the meth-
335 od sensitivity they have chosen a volume of saliva of 1,2 mL. After extraction, the meth-
336 od involves static washing with deionized water (1.5 mL) to remove matrix components
337 from the surface of the coating and prevent subsequent desorption, no loss of analytes
338 was detected after this step.

339 The optimal conditions of desorption for all analytes were 90 min in acetoni-
340 trile/water 80:20 (*v: v*). The LOQ were 178, 22, 105, 185, 29 and 16 pg mL⁻¹ for cortisol,
341 testosterone, progesterone, E3, E2 and E1, respectively. This method has showed ad-
342 vantages in term of high sensitivity, reproducibility, and accuracy for detection of en-
343 dogenous steroids in saliva. These characteristics makes the method better than the
344 common immunoassays which may lead to erroneous results due to the significant
345 cross-reaction; the validated SPME method had showed better results than liquid-liquid
346 extraction (LLE) thanks to a cleaner extract that prevent matrix effects. Moreover, it was
347 observed that *in vivo* sampling had a better efficiency than *ex vivo* sampling of saliva.
348 [44]

349 In recent years, a new special application of SPME technique was observed that in-
350 cludes *in vivo* analysis. This method combines the advantages of SPME technique for
351 sample preparation that requires no or small amount of organic solvent and the ad-
352 vantages of the *in vivo* sampling that eliminates errors related to degradation or loss of
353 short-life or unstable analytes; moreover, with this sampling method, it was possible to
354 sample over time the same individual (e.g. drug monitoring).

355 SPME was coupled to GC-MS or LC-MS/MS to separate and detect analytes, or di-
356 rectly to MS. Usually this extraction technique depends on the fiber and matrix charac-
357 teristics. Different SPME coating fibers has been employed to determine numerous
358 compounds with different volatility and polarity in complex matrices: CAR/PDMS
359 (Carboxen/polydimethylsiloxane) have been used to determine VOCs while PDMS-DVB
360 fibers have been used to determine non-polar or weakly polar VOCs with GC-MS analy-
361 sis, drugs and metabolites with direct MS and endogenous hydrocarbons in human
362 breath with GC-MS.

363 Different methods have been developed with this *in vivo* procedure for
364 non-invasive and sensitive determination of different bio analytes in different types of
365 samples in different fields of applications.

366 Amongst complex matrices used for *in vivo* SPME methods, the easiest to sample is
367 the skin with a direct contact of SPME fiber placed on the skin surface, also breath and
368 saliva can be used to obtain *in vivo* pathophysiological information.

369 For example, VOCs in human exhaled breath or emanating from human skin are
370 potentially used as biomarkers for different disease diagnosis.

371 The methodology of *in vivo* SPME of VOCs in human skin was used to record the
372 VOC profile in skin cancer (e.g., basal cell carcinoma), fibrotic skin disorders or vascular
373 lesions. In addition, VOCs in human breath are useful in diagnosis of lung cancer, liver
374 disease, myocardial infarction, or diabetes. [45]
375

376 3.2 Microextraction by Packed Sorbent (MEPS)

377 Microextraction by packed sorbent (MEPS) is a miniaturized SPE technique with
378 very interesting potential benefits, such as low solvent volume for analytes elution,
379 small sample volume (10–250 μL), direct injection without further treatments, simple
380 operation, and cost-effectiveness. In this procedure, about 1–2 mg of sorbent (such as
381 C18, C8) is packed in the barrel of a gas-tight syringe positioned between the needle and
382 the barrel as a cartridge. When the sample has passed through the solid bed, the analytes
383 were adsorbed into the sorbent. [38]

384 Ghimenti et al. validated an innovative method that combined MEPS with ul-
385 tra-high-performance liquid chromatography coupled to electrospray ionization tri-
386 ple-quadrupole mass spectrometry (UHPLC-ESI-MS/MS) for the simultaneous determi-
387 nation of 8-isoprostaglandin F₂ α (8-isoPGF₂ α) and cortisol in saliva samples collected
388 from patients with heart failure. During the optimization of this method, they maxim-
389 ized the extraction efficiency of 8-isoPGF₂ α and cortisol with dilution of saliva samples
390 with water (ratio 1:5, *v/v*) and filtration by syringe filter prior to MEPS extraction to
391 avoid proteins, mucins and other interferences that may cause deterioration of the
392 sorbent and cartridge clogging, without loss of analytes. A LOD of 10 pg/mL was ob-
393 tained for each target analytes; the coefficient of determination (R^2) was 0.7 and p-value
394 < 0.001.

395 Compared to other techniques such as enzyme-linked immunosorbent assays
396 (ELISA) which may lead to partially inaccurate results or solid phase extraction (SPE)
397 procedures, which requires a larger volume of samples, a substantial problem for saliva
398 analysis, the obtained results with MEPS showed that this is a good alternative with dif-
399 ferent advantages. MEPS procedure required low volume of organic solvents (<100
400 μL /measurement), a reusable sorbent (over 100 extractions with the same cartridge),
401 permits to automate the extraction procedure with reduction of the cost of analysis. In
402 addition, this procedure showed a satisfactory recovery (95–110%) and an adequate limit
403 of detection, which guarantee a reliable determination of low concentration levels of
404 8-isoPGF₂ α and cortisol in real saliva samples. The obtained results confirmed that the
405 MEPS method allows a reliable quantification of 8-isoPGF₂ α and cortisol as new poten-
406 tial non-invasive biomarkers for monitoring patient with heart failure and useful for
407 clinical purposes [46].

408 Berenguer et al. developed a highly sensitive MEPS/UHPLC method to detect and
409 quantify lipid peroxidation biomarkers such as leukotrienes E₄ (LTE₄), B₄ (LTB₄) and
410 11 β -prostaglandin F₂ α (11 β PGF₂ α) related to asthma, in urine of child patients. The tar-
411 getted analytes were isolated from urine using a semiautomatic miniaturization of solid
412 phase extraction, the MEPS; the LOD for LTB₄ and 11 β PGF₂ α was respectively 0.04 μg
413 $\mu\text{g L}^{-1}$ and 1.12 $\mu\text{g L}^{-1}$ while LOQ values ranged between 0.10 $\mu\text{g L}^{-1}$ for the LTB₄ and 2.11
414 $\mu\text{g L}^{-1}$ for 11 β PGF₂ α . Compared to other methodologies, this technique had showed
415 more advantages such as lower elution solvent volume consumption, high precision due
416 to the semi-automatic procedure, excellent recoveries and extraction efficiency. Moreo-
417 ver, the extraction procedure is fast with a total analysis time of 31 min. The obtained
418 values for the 11 β PGF₂ α and LTB₄ were about 1.8 times higher, and for the LTE₄ were
419 about 1.4 times higher in asthmatic patients than in healthy individuals suggesting the
420 potential of these eicosanoids on asthma diagnosis. Consequently, MEPS/UHPLC-PDA
421 represents a promising method for simultaneous detection of these and other eico-

sanoids present in other biological matrices as plasma or saliva of patients with different inflammatory diseases. [47]

3.3 Dispersive Liquid-Liquid Microextraction (DLLME)

Dispersive liquid–liquid microextraction (DLLME) is a type of sample preparation based on liquid phase microextraction (LPME) technique in which the target analytes are extracted from an aqueous solution with small volumes of extraction solvent. In DLLME, the dispersion procedure increases the extraction kinetics by enlarging the exposure surface between the sample and the extractant, then the emulsion was centrifuged and the extractant was isolated. This technique showed several advantages such as easy operation, low sample volume, rapid processing with high recovery without necessity of any appliance. [48]

Zhou et al. validate an easy method of sample preparation with high-efficiency based on ultrasound-assisted ionic liquid dispersive liquid–liquid microextraction (UA-IL-DLLME), for simultaneous determination of neurotransmitters (NTs) such as γ -aminobutyric acid (GABA), acetylcholine (Ach) and glutamic acid (Glu) in mild cognitive impairment, mild dementia, and moderate dementia patients’ urine samples. The analysis of clinical samples showed that some NTs presented significant differences in different dementia stages. This method showed many advantages such as selectivity, stability, sensitivity, and simple procedure of sample preparation, thanks to these characteristics the validated strategy of preparation and analysis might be used also with different type of biological samples. [49]

Table 2. Microextraction techniques used for diagnostic purposes.

Target analytes	Matrix	Extraction technique	Analytical characteristics	Ref.
Dopamine (DA), Serotonin (5-HT), Norepinephrine (NE)	Human urine	SPME-GC-QqQ-MS	DA: LOD 0,59 $\mu\text{g L}^{-1}$, LOQ 0,81 $\mu\text{g L}^{-1}$ 5-HT: LOD 0,38 $\mu\text{g L}^{-1}$, LOQ 0,74 $\mu\text{g L}^{-1}$ NE: LOD 13,5 $\mu\text{g L}^{-1}$, LOQ 21,3 $\mu\text{g L}^{-1}$	[41]
Homovanillic acid (HVA), vanilylmandelic acid (VMA), 5-hydroxyindolacetic acid (5-HIAA)	Human urine	SPME-GC-QqQ-MS	HVA: LOD 1,3 $\mu\text{g L}^{-1}$, LOQ 2,7 $\mu\text{g L}^{-1}$ VMA: LOD 0,046 $\mu\text{g L}^{-1}$, LOQ 0,063 $\mu\text{g L}^{-1}$ 5-HIAA: LOD 24,3 $\mu\text{g L}^{-1}$, LOQ 49,6 $\mu\text{g L}^{-1}$	[50]
VOCs	Human Breathe	MESI-GC	LOD Acetone 0,4 $\mu\text{g/L}$ LOD Ethanol 0,5 $\mu\text{g/L}$	[51]
F2-isoprostanes	Human plasma Urine	SPE-GC-MS	LOD (plasma) 0,037 ng/mL LOD (urine) 0,007 ng/mg	[52]
LTB4	Human urine	MEPS-UHPLC-PDA	LOD 0,37 ng/mL LOQ 1,22 ng/mL	[53]

Metanephrine (MN) Normetanephrine (NMN)	Human plasma	MEPS-HILIC-MS/MS	NM LOD 12,4 pg/mL NMN LOD 12,3 pg/mL	[54]
Dopamine (DA), Norepinephrine (NE), Metanephrine (MN), Normetanephrine (NMN), L-3,4-dihydroxyphenylalanine (L-DOPA), Epinephrine (E), Epinephri- ne-d6 (E-d6), Metanephrine-d3 (MN-d3), Normetanephrine-d3 (NMN-d3), Sero- tonin (5-HT), Testosterone (T), Epi-tes- tosterone (EpiT), Dihydrotestosterone (DHT), 17-hydroxyprogesterone (17-OHP); An- drostenedione (A), Progesterone (P4), Epi-testosterone-d3 (EpiT-d3)	Human urine	LLE-LC/MS	DA: LOD 1 ng/mL NE: LOD 1 ng/mL MN: LOD 1 ng/mL NMN: LOD 1 ng/mL L-DOPA: LOD 20 ng/mL E: LOD 1 ng/mL E-d6: LOD 1 ng/mL MN-d3: LOD 1 ng/mL NMN-d3: LOD 1 ng/mL 5-HT: LOD 1 ng/mL T: LOD 1 ng/mL EpiT: LOD 1 ng/mL DHT: LOD 1 ng/mL 17-OHP: LOD 1 ng/mL A: LOD 1 ng/mL P4: LOD 1 ng/mL EpiT-d3: LOD 1 ng/mL	[55]
Norepinephrine (NE)	Artificial urine	Rotating-disk sorp- tive extraction tech- nique (RDSE)	NE: LOD 11,3 µg L-1, LLOQ 34,0 µg L-1 EPI: LOQ 0.167 ng/mL, LOD 0.0800 ng/mL NE: LOQ 0.650 ng/mL, LOD 0.300 ng/mL DA: LOQ 1.53 ng/mL, LOD 0.530 ng/mL	[56]
Epinephrine (EPI), Norepinephrine (NE), Dopamine (DA), Metanephrine (MN), Normetanephrine (NMN), 3-methoxytyramine (3-MT)	Human urine	MEPS-LC-MS/MS	MN: LOQ 0.440 ng/mL, LOD 0.176 ng/mL NMN: LOQ 1.10 ng/mL, LOD 0.440 ng/mL 3-MT: LOQ 0.880 ng/mL, LOD 0.176 ng/mL	[57]

445

446

447

448

449

450

451


452

3.4 Fabric Phase Sorptive Extraction (FPSE)

Fabric phase sorptive extraction (FPSE) is an innovative technique developed by Kabir and Furton [58] that offers substantial simplification of the selective extraction of the target analytes from biological samples. Now-a-days, thanks to the new analytical methods based on FPSE, it is possible to determine low concentrations of analytes with no/minimal sample pretreatment. In addition, the several steps in the treatment of complex biological matrices (for example whole blood, urine, saliva etc.) such as protein pre-

453 precipitation, sonication, elution of extract in an organic solvent, solvent evaporation and
 454 sample reconstitution often the cause of most of the errors during the analytical process
 455 can be eliminated from the sample preparation workflow when FPSE is used. [59]
 456 Briefly, when the FPSE membrane is immersed into the aqueous sample, the analyte(s)
 457 permeates through the sol-gel sorbent like an SPE disk and establishes intermolecular
 458 interaction. However, at the same time, the analyte(s) continue to accumulate on the
 459 FPSE membrane based on the partition coefficient between the sol-gel sorbent and the
 460 sample matrix. Therefore, this novel technique combines both the exhaustive extraction
 461 principle and the equilibrium driven-extraction principle by design. [60]
 462 Samanidou et al. used three FPSE membranes in particular, sol-gel poly(dimethyldiphenylsiloxane)
 463 (sol-gel PDMDPS), sol-gel poly (tetrahydrofuran) (sol-gel PTHF) and sol-gel poly (ethylene glycol)
 464 (sol-gel PEG) to determinate benzodiazepines from human blood serum. The authors demonstrated
 465 the simplicity of this extraction, in terms of the number of operations in comparison with other
 466 innovative techniques, like SPE. [59]
 467

468 **Fig. 2** Comparison between solid phase extraction (SPE) and fabric phase sorptive ex-
 469 traction (FPSE)



470
 471 As shown above, Locatelli M. et al. integrate the FPSE with HPLC-DAD for separation
 472 and quantification of anastrozole, letrozole and exemestane from whole blood, plasma,
 473 and urine. The first step was the creation of sol-gel sorbent coated membrane: selection
 474 of appropriate substrate and its pre-treatment, design of the most appropriate sol solu-
 475 tion to obtain maximum selectivity, coating the pre-treated fabric substrate with sol-gel
 476 sorbent and conditioning and cleaning the FPSE membrane. Membranes were cut to
 477 have an identical surface area with an internal diameter of 1 cm, they were washed first
 478 with acetonitrile: methanol (50:50, v/v) and then with milliQ water. Subsequently, the
 479 conditioned membranes were inserted into the sample (diluted whole blood, plasma,
 480 and urine) and were left for 30 minutes on the rotator. After this time, the analytes ex-
 481 tracted were eluted from FSPE membranes using methanol, and the eluant was centrif-

482 ugated. An aliquot from obtained supernatant was directly injected into the HPLC-DAD
483 for the analysis. [22]

484 Tartaglia et al. used eight different FPSE membranes for preliminary experiments to ex-
485 tract antidepressant drugs from conventional biological matrices (plasma and urine) and
486 unconventional biological matrices (human saliva). For the optimization of the extrac-
487 tion process, all the parameters were gradually optimized to obtain the maximum ex-
488 traction efficiency of the compounds. After the activation of the membranes, the initial
489 general conditions have been tested: each support was immersed in 500 μ L of standard
490 solution for 30 minutes under stirring and then each membrane was immersed in 150 μ L
491 of MeOH for 30 min for analyte back-extraction. Subsequently, other parameters were
492 optimized: extraction time, elution solvents and mixtures, back extraction time and
493 volume. After selection of optimal condition using standard solutions, the optimization
494 was performed on the biological complex matrices mentioned previously. [61]

495 In the same way, Locatelli et al. have optimized all parameters to obtain the maximum
496 extraction of twelveazole antimicrobial drugs residues from human plasma and urine.
497 They have investigated three different FPSE membranes, and different dimensions of
498 these, to study the optimum sample volume and the optimum extraction media dimen-
499 sion. [36]

500 Kabir A. et al. have used this simple and powerful technique combined with
501 HPLC-DAD for simultaneous monitoring of three anti-inflammatory drugs (ciprofloxacin,
502 sulfasalazine, and cortisone) using in treatment of inflammatory bowel disease.
503 They have tested five different FPSE membranes coated with different sorbent and dif-
504 ferent extraction parameters to develop an extraction procedure for molecules that are
505 characterized by a wide range of LogP. [31]

506 Gazioglu I. et al. have combined FPSE-extraction with HPLC-fluorimetric detection to
507 quantify simultaneously Febuxostat and Montelukast in human blood. [62]

508 Recently FPSE extraction was also used by Tiris G. et al. to extract an anti-viral drug
509 from breast milk [63] and was also applied for *in vivo* non-invasive exhaled breath aero-
510 sol sampling to monitoring the exposure to xenobiotics by Locatelli M. et al. [64-66]

511 The amazing benefits of FPSE as a new generation sample preparation technique were
512 further manifested in a study presented by G. Sidiropoulou et al. [67] where FPSE was
513 combined with UPLC-ESI-MS/MS to monitor the presence of residual antiviral drugs in-
514 cluding amantadine, memantine, and rimantadine in human urine. Sol-gel
515 poly(propylene glycol)-poly(ethylene glycol)-poly(propylene glycol) coated FPSE mem-
516 brane reached extraction equilibrium in just 20 min, thanks to the rapid mass transfer of
517 the target analytes from the bulk of the sample to the FPSE membrane due to the engi-
518 neered affinity of the sol-gel sorbent towards the target analytes via different intermo-
519 lecular interactions and the sponge-like porous structure of the sol-gel sorbent. A matrix
520 matched calibration curve was developed in the range of 5-100 ng ml⁻¹ to aid the quanti-
521 tative analysis of the target analytes in unknown clinical samples. The FPSE combined
522 with UPLC-ESI-MS/MS method provides LOD values in the range of 0.2-0.8 ng/mL and
523 LOQ value of 5 ng/mL for all target analytes. It is worth mentioning that, unlike other
524 sample preparation techniques, FPSE didn't require any kind of pretreatment of urine
525 sample prior to the extraction of analytes on FPSE membrane.

526 Another interesting study presented by K. Mazaraki et al. [68] where the researchers in-
527 vestigated the presence of traces of six beta-blockers possessing widely varied logP val-
528 ues (from 0.1 to 3.1) in human serum and urine using FPSE as the sample preparation
529 technique followed by UHPLC-ESI-MS/MS as the chromatographic technique. Sol-gel
530 CW 20M sorbent coated on 100% cotton cellulose was identified as the most efficient

531 FPSE membrane for the target analytes. After optimizing all the FPSE parameters, the
532 FPSE-UHPLC-ESI-MS/MS composite method provided LOD values for the selected be-
533 ta-blockers from 0.3-2 ng/mL and the LLOQ values were calculated as 50 ng/mL in both
534 serum and urine samples. The method was linear in the broad range of 50-5000 ng/mL.

535 G. Tris et al. [63] described an FPSE method followed by HPLC-UV analysis designed to
536 monitor Favipiravir, a promising antiviral agent for the treatment of corona virus, in
537 human plasma and breast milk samples. Overall chromatographic run was only 5 min.
538 The LOQ values of the validated method were 0.2 µg/mL in plasma and 0.5 µg/mL.

539 By eliminating the protein precipitation and other sample pretreatment steps from the
540 sample preparation workflow, FPSE has established itself as a rapid, simple, and green
541 sample preparation technique for forensic toxicology. Recently, M. Locatelli et al. [69]
542 have proved the operational simplicity and performance superiority of FPSE in pro-
543 cessing post-mortem samples including whole blood and cerebrospinal liquor collected
544 during autopsy to monitor seven common antidepressant drugs. Sol-gel CW20M coated
545 FPSE membrane was identified as the best FPSE sorbent for the selected drugs with an
546 optimum extraction time of 20 min, back-extraction time of 5 min and 150 µL of metha-
547 nol as the eluent. The overall chromatographic run time was 20 min. The LOQ values
548 were 0.1 µL/mL for all drug compounds except Venlafaxine, which was 0.2 µL/mL.

549
550 The performance superiority, simplicity, and easiness in application of this novel tech-
551 nique have been demonstrated in many articles and reviews, in extractions from com-
552 plex sample matrices.

553 4. Conclusions

554 As can be seen from the manuscript, last several years were important to develop new
555 strategies and techniques to apply in bioanalytical studies. The principal aim was to
556 maximize the performance with these samples in term of efficiency and operational
557 steps and speed, complying with green chemistry principles and the possibilities to use
558 them for different applications. It is important to emphasize the diversification of the
559 samples, from conventional samples as whole blood or urine to unconventional like sa-
560 liva or breast milk, but at the same time duration of the sample preparation workflow,
561 efficiency, reproducibility, and the potential reuse of the sample preparation device to
562 reduce the overall analytical cost. Moreover, the wide range of samples can be applied in
563 different clinical analysis, useful for research's progress. Clinical analysis includes dif-
564 ferent studies like pharmacokinetics studies or studies that may help in a specific treat-
565 ment regimen or, also, studied that diagnose some pathologies. Therefore, the employ-
566 ment of different matrices means different approaches in terms of preparation and
567 pre-treatment, and it follows the possibilities to differ specific studies. For complex sam-
568 ple matrices, the principal issue can be the pre-treatment and extraction of the sample, in
569 fact often the pre-treatment is the principal cause of error. This is the primary rationale
570 as to why we discussed about new techniques, easy for operators, simple to execute and
571 capable of reducing overall sample preparation time and number of steps involved.

572 **Supplementary Materials:** This work is a review paper. No supplementary materials are pre-
573 sented.

574 **Author Contributions:** All Authors contributed equally in terms of data curation, writing, and ed-
575 iting. M.L., A.G., F.S., U.d.G., A.K., H.I.U., C.D.O., I.A.: conceptualization; M.L., A.G., F.S., U.d.G.,
576 A.K., H.I.U., C.D.O., I.A.: Supervision and Project Administration; V.G., O.M., E.R., M.P., L.C.,
577 M.L., A.G., F.S., U.d.G., A.K., H.I.U., C.D.O., I.A.: Writing—Original Draft Preparation and Writ-

ing—Review & Editing, All authors have read and agreed to the published version of the manuscript.

Funding: This review paper has not received any funding.

Institutional Review Board Statement: Not applicable, review paper.

Informed Consent Statement: Not applicable, review paper.

Data Availability Statement: Data and information are available on request to the authors.

Acknowledgments: Authors would like to thank the University “G. d’Annunzio” for the support in the literature survey.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. D’Ovidio, C.; Bonelli, M.; Rosato, E.; Tartaglia, A.; Ulusoy, H.I.; Samanidou, V.; Furton, K.G.; Kabir, A.; Ali, I.; Savini, F.; Locatelli, M.; de Grazia, U.. Novel Applications of Microextraction Techniques Focused on Biological and Forensic Analyses. *Separations*. **2022**, *9*, 18.
2. Ingle, R.G.; Zeng, S.; Jiang, H.; Fang, W.J. Current developments of bioanalytical sample preparation techniques in pharmaceuticals. *J. Pharm. Anal.* **2022**, *12*, 517-529.
3. Pandey, K.; Mishra, O.P. Advancement in Analytical and Bioanalytical Techniques as a Boon to Medical Sciences. In *Biochemical Testing*. Bobbarala, V., Zaman, G.S., Desa, M.N.M., Akim, A.M., IntechOpen; London, United Kingdom, 2020; 12, 29-46.
4. Pourshamsi, T.; Amri, F.; Abniki, M. A comprehensive review on application of the syringe in liquid and solid phase microextraction methods. *J. Iran. Chem. Soc.* **2021**, *18*, 245–264. <https://doi.org/10.1007/s13738-020-02025-7>
5. Hansen, F.A.; Pedersen-Bjerggaard, S. Emerging Extraction Strategies in Analytical Chemistry. *Anal. Chem.*, **2020**, *92*, 2-15.
6. Knikma, J.E.; Rosing, H.; Guchelaar, H.J.; Cats, A.; Beijnen, J.H. A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. *Biomed Chromatogr.* **2020**, *34*, 1-12
7. Zufia, L.; Aldaz, A.; Giraldez, J. , Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. *J Chromatogr B* **2004**, *809*, 51-58
8. Piórkowska, E.; Kaza, M.; Fitatiuk, J.; Szlaska, I.; Pawinski, T.; Rudzki P.J. Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma. *Pharmazie*. **2014**, *69*, 500-505
9. Licea-Perez, H.; Wang, S.; Bowen, C. Development of a sensitive and selective LC-MS/MS method for the determination of α -fluoro- α -alanine, 5-fluorouracil and capecitabine in human plasma. *J Chromatogr B* **2009**, *877*, 1040-1046
10. Salvador, A.; Millerioux, L.; Renou A. Simultaneous LC-MS-MS Analysis of Capecitabine and its Metabolites (5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil) After OffLine SPE from Human Plasma. *Chromatogr.* **2006**, *63*, 609-615
11. Buchner, P.; Mihola, E.; Sahmanovic, A.; Steininger, T.; Dittrich, C.; Czejka, M.. Validation of a Simple Assay for the Quantification of the Capecitabine Metabolites 5'-DFCR and 5'-DFUR for Drug Monitoring in Patients Receiving Outpatient Chemotherapy. *Anticancer Res.* **2013**, *33*, 881-886
12. Farkouh, A.; Ettlinger, D.; Schueller, J.; Georgopoulos, A.; Scheithauer, W.; Czejka, M. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes. *Anticancer Res.* **2010**, *30*, 5207-5211
13. Xu, Y.; Grem, J.L. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma. *J Chromatogr B* **2003**, *783*, 273-285
14. Deng, P.; Ji, C.; Dai, X.; Zhong, D.; Ding, L.; Chen, X. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. *J Chromatogr B* **2015**, *989*, 71-79

- 619 15. Thorat, S.G.; Chikhale, R.V.; Tajne, M.R. A rapid and simple HPTLC assay for therapeutic drug monitoring of capecitabine in
620 colorectal cancer patients. *Biomed Chromatogr.* **2018**, *32*, 1-6
- 621 16. Guichard, S.M.; Mayer, I.; Jodrell, D.I. Simultaneous determination of capecitabine and its metabolites by HPLC and mass
622 spectrometry for preclinical and clinical studies. *J Chromatogr B* **2005**, *826*, 232-237
- 623 17. Vainchtein, L.D.; Rosing, H.; Schellens, J.H.M.; Beijnen, J.H. A new, validated HPLC-MS/MS method for the simultaneous de-
624 termination of the anti-cancer agent capecitabine and its metabolites: 50 - deoxy-5- fluorocytidine, 50 -deoxy-5-fluorouridine,
625 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. *Biomed Chromatogr.* **2010**, *24*, 374-386
- 626 18. Wang, Z.; Li, X.; Yang, Y.; Zhang, F.; Li, M.; Chen, W.; Gao, S.; Chen, W. A Sensitive and Efficient Method for Determination of
627 Capecitabine and Its Five Metabolites in Human Plasma Based on One-Step LiquidLiquid Extraction. *J Anal Methods Chem.*
628 **2019**, 9371790, 1-10
- 629 19. Deenen, M.J.; Rosing, H.; Hillebrand, M.J.; Schellens, J.H.M.; Beijnen, J.H. Quantitative determination of capecitabine and its six
630 metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. *J Chromatogr B*
631 **2013**, 913-914, 30-40
- 632 20. Fresnai, M.; Roth, A.; Foerster, K.I.; Jäger, D.; Pfister, S.M.; Haefeli, W.E.; Burhenne, J.; Longuespée, R. Rapid and Sensitive
633 Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IM-MS/MS Assay. *Cancers.* **2020**, *17*, 1897
- 634 21. Llopis, B.; Robidou, P.; Tissot, N.; Pinna, B.; Gougis, P.; Aubart, F.C.; Campedel, L.; Abbar, B.; Weil, D.R.; Uzunov, M.;
635 Gligorov, J.; Salem, J.E.; Funck-Brentano, C.; Zahr, N. Development and clinical validation of a simple and fast
636 UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human
637 plasma: Interest for their therapeutic drug monitoring. *J Pharm Biomed Anal.* **2021**, *197*, 113968
- 638 22. Locatelli, M.; Tinari, N.; Grassadonia, A.; Tartaglia, A.; Macerola, D.; Piccolantonio, S.; Sperandio, E.; D'Ovidio, C.; Carradori,
639 S.; Ulusoy, H.I.; Furton, K.G.; Kabir, A. FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole
640 blood, plasma, and urine, *J Chromatogr B* **2018**, *1095*, 204-213
- 641 23. Ferrari, D.; Ripa, M.; Premaschi, S.; Banfi, G.; Castagna, A.; Locatelli, M. LC-MS/MS method for simultaneous determination of
642 linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. *Journal of Pharmaceutical and biomedical*
643 *analysis. J Pharm Biomed Anal.* **2019**, *169*, 11-18
- 644 24. Wongchang, T.; Winterberg, M.; Tarning, J.; Sriboonvorakul, N.; Muangnoicharoen, S.; Blessborn, D. Determination of
645 ceftriaxone in human plasma using liquid chromatography-tandem mass spectrometry. *Wellcome Open Res.* **2021**, *4*, 47
- 646 25. Krnac, D.; Reiffova, K.; Rolinski, B. A new HPLC-MS/MS analytical method for quantification of tazobactam, piperacillin, and
647 meropenem in human plasma. *J Sep Sci.* **2021**, *44*, 2744-2753
- 648 26. Rola, R.; Kowalski, K.; Bienkowski, T.; Studzinska, S. Improved sample preparation method for fast LC-MS/MS analysis of
649 vitamin D metabolites in serum. *J Pharm Biomed Anal.* **2020**, *190*, 1-10
- 650 27. Hotta, K.; Wang, Y.; Mano, Y. A sensitive bioanalytical assay for methylcobalamin, an endogenous and light-labile substance,
651 in human plasma by liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. *J*
652 *Pharm Biomed Anal.* **2020**, *191*, 1-7
- 653 28. Bollen, P.D.J.; de Graaff-Teulen, M.J.A.; Schalkwijk, S.; van Erp, N.P.; Burger, D.M. Development and validation of an
654 UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, ral-
655 tegravir, nevirapine and etravirine in human plasma. *J Chromatogr B* **2019**. 1105, 76-84.
- 656 29. Elkadya, E.F.; Aboelwaf, A.A. Rapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and
657 velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers. *J Chromatogr B* **2018**. 1102-1103,
658 116-124.

- 659 30. Raabová H., Havlíková L. C., Erben J., Chvojka J., Švec F. and Šatínský D. Polycaprolactone Composite Micro/Nanofibrous
660 Material as an Alternative to Restricted Access Media for Direct Extraction and Separation of Non-Steroidal Anti-Inflammatory
661 Drugs from Human Serum Using Column-Switching Chromatography. *Nanomaterials*, **2021**, 11(10), 2669
- 662 31. Kabir A., Furton K. G., Tinari N., Grossi L., Innosad D., Macerola D., Tartaglia A., Di Donato V., D'Ovidio C., Locatelli M.
663 Fabric phase sorptive extraction-high performance liquid chromatography photo diode array detection method for simulta-
664 neous monitoring of three inflammatory bowel disease treatment drugs in whole blood, plasma and urine. *J. Chromatogr. B*,
665 **2018**, 1084, 53-63
- 666 32. Tartaglia A., Kabir A., D'Ambrosio F., Ramundo P., Ulusoy S., Ulusoy H.I., Merone G.M., Savini F., D'Ovidio C., De Grazia U.,
667 Furton K.G., Locatelli M. Fast off-line FPSE-HPLC-PDA determination of six NSAIDs in saliva samples. *J. Chromatogr. B*, **2020**,
668 1144, 9.
- 669 33. D'angelo V., Tessari F., Bellagamba G., De Luca E., Cifelli R., Celia C., Primavera R., Di Francesco M., Paolino D., Di Marzio L.,
670 Locatelli M., Microextraction by packed sorbent and HPLC-PDA quantification of multiple anti-inflammatory drugs and
671 fluoroquinolones in human plasma and urine, *J. Enz. Inhib. Med. Chem.*, **2016**, 31(sup3), 110-116.
- 672 34. Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Saldanha S. A., Buclin T., Marzolini C., Csajka C., Decoster L.A.
673 UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with
674 its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV, *J.*
675 *Chromatogr B*. **2019**, 1125, 11.
- 676 35. Campestre C., Locatelli M., Guglielmi P., De Luca E., Bellagamba G., Menta S., Zengin G., Celia C., Di Marzio L. and Carradori
677 S.. Analysis of imidazoles and triazoles in biological samples after MicroExtraction by packed sorbent. *J. Enz. Inhib. med. chem.*,
678 **2017**, 32(1), 1053-1063.
- 679 36. Locatelli M., Kabir A., Innosa D., Lopatriello T., Furton K.G. A fabric phase sorptive extraction-High performance liquid
680 chromatography-Photo diode array detection method for the determination of twelve azole antimicrobial drug residues in
681 human plasma and urine. *J. Chromatogr. B*. **2017**, 1040, 192-198.
- 682 37. Kabir, A.; Locatelli, M.; Ulusoy, H.I. Recent Trends in Microextraction Techniques Employed in Analytical and Bioanalytical
683 Sample Preparation. *Separations* **2017**, 4, 36
- 684 38. Locatelli M., Tartaglia A., Piccolantonio S., Di Iorio L.A., Sperandio E., Ulusoy H.I., Furton K.G., Kabir A. Innovative configura-
685 tions of sample preparation Techniques Applied in bioanalytical chemistry: A review. *Curr. Anal. Chem.*, **2019**, 15, 731-744.
- 686 39. Ingle R. G., Zeng S., Jiang H., Fang W.-J., Current developments of bioanalytical sample preparation techniques in pharma-
687 ceuticals. *J. Pharm. Anal* **2022**, 12, 517-529.
- 688 40. Matys J., Gieroba B., Jó'zwiak K., Recent developments of bioanalytical methods in determination of neurotransmitters in vivo.
689 *J. Pharm. Biomed. Anal.* **2020**, 180, 12.
- 690 41. Naccarato A., Gionfriddo E., Sindona G., Tagarelli A., Development of a simple and rapid solid phase microextraction-gas
691 chromatography-triple quadrupole mass spectrometry method for the analysis of dopamine, serotonin and norepinephrine in
692 human urine, *Anal. Chim. Acta*, **2014**, 810, 17-24.
- 693 42. Monteiro M., Carvalho M., Henrique R., Jeronimo C., Moreira N., de Lourdes Bastos M., de Pinho P.G., Analysis of volatile
694 human urinary metabolome by solid-phase microextraction in combination with gas chromatography-mass spectrometry for
695 biomarker discovery: Application in a pilot study to discriminate patients with renal cell carcinoma, *Europ. J. Cancer*, **2014**, 50,
696 1993-2002.
- 697 43. Deev V., Solovieva S., Andreev E., Protoshchak V., Karpushchenko E., Sleptsov A., Kartsova L., Bessonova E., Legin A.,
698 Kirsanov D. Prostate cancer screening using chemometric processing of GC-MS profiles obtained in the headspace above urine
699 samples, *J. Chromatogr. B*, **2020**, 1155, 8.

- 700 44. Bessonneau V., Boyaci E., Maciazek-Jurczyk M., Pawliszyn J. In vivo solid phase microextraction sampling of human saliva for
701 non-invasive and on-site monitoring, *Anal. Chim. Acta*, **2015**, 856, 35–45.
- 702 45. Costa Queiroz M. E., Donizeti de Souza I., de Oliveira I. G., Grecco C. F. In vivo solid phase microextraction for bioanalysis,
703 *TrAC*, **2022**, 153, 18.
- 704 46. Ghimenti S., Lomonaco T., Bellagambi F. G., Biagini D., Salvo P., Trivella M. G., Scali M. C., Barletta V., Marzilli M., Di Fran-
705 cesco F., Errachid A., Fuoco R. Salivary lactate and 8-isoprostaglandin F2á as potential non-invasive biomarkers for monitoring
706 heart failure: a pilot study, *Scientific Reports*, **2020**, 10, 7441
- 707 47. Berenguer P.H., Camacho I.C., Câmara R., Oliveira S., Câmara J.S. Determination of potential childhood asthma biomarkers
708 using a powerful methodology based on microextraction by packed sorbent combined with ultra-high pressure liquid chro-
709 matography. Eicosanoids as case study, *J. Chromatogr. A*, **2019**, 1584, 42–56.
- 710 48. Ingle R. G., Zeng S., Jiang H., Fang W.-J. Current developments of bioanalytical sample preparation techniques in pharmaceu-
711 ticals, *J. Pharm. Anal.* **2022**, 12, 517-529.
- 712 49. Zhou G.-S., Yuan Y.-C., Yin Y., Tang Y.P., Xu R.-J., Liu Y., Chen P.-D., Yin L., Duan J.-A. Hydrophilic interaction chromatog-
713 raphy combined with ultrasound-assisted ionic liquid dispersive liquid-liquid microextraction for determination of underi-
714 vated neurotransmitters in dementia patients' urine samples, *Anal. Chim. Acta* **2020**, 1107, 74-84.
- 715 50. Monteleone M., Naccarato A., Sindona G., Tagarelli A. A reliable and simple method for the assay of neuroendocrine tumor
716 markers in human urine by solid-phase microextraction–gas chromatography-triple quadrupole mass spectrometry, *Anal.*
717 *Chim. Acta* **2013** 759, 66–73.
- 718 51. Lord H., Yu Y., Segal A., Pawliszyn J., Breath analysis and monitoring by membrane extraction with sorbent interface, *Anal.*
719 *Chem*, **2002**, 74. 5650-5657.
- 720 52. Lee C. Y. J., Jenner A.M., Halliwell B. Rapid preparation of human urine and plasma samples for analysis of F 2-isoprostanes
721 by gas chromatography-mass spectrometry. *Biochem. Biophys. Res. Commun.* 2004, 320, 696–702.
- 722 53. Perestrelo R., Silva C. L., Câmara J. S. Determination of urinary levels of leukotriene B4 using a highly specific and sensitive
723 methodology based on automatic MEPS combined with UHPLC-PDA analysis, *Talanta* **2015**, 144, 382–389.
- 724 54. Xiong X., Zhang Y., Zhao R. Quantitative Measurement of Plasma Free Metanephrines by a Simple and Cost-Effective Micro-
725 extraction Packed Sorbent with Porous Graphitic Carbon and Liquid Chromatography-Tandem Mass Spectrometry, *J. Anal.*
726 *Met. in Chem.* **2021**, 2021, 1-11.
- 727 55. Lee Y.-R., Lew B.-L., Sim W.-Y., Hong J., Chung B.-C. Serial Hydrolysis for the Simultaneous Analysis of Catecholamines and
728 Steroids in the Urine of Patients with Alopecia Areata. *Molecules*. **2021**, 26, 2734.
- 729 56. Castillo-Aguirre A., Maldonado M. Preparation of Methacrylate-Based Polymers Modified with Chiral Resorcinarenes and
730 Their Evaluation as Sorbents in Norepinephrine Microextraction, *Polymers*, **2019**, 11, 1428.
- 731 57. Xiong X., Zhang Y. Simple, rapid, and cost-effective microextraction by the packed sorbent method for quantifying of urinary
732 free catecholamines and metanephrines using liquid chromatography-tandem mass spectrometry and its application in clinical
733 analysis, *Anal. Bioanal Chem.*, **2020**, 412, 2763–2775.
- 734 58. Kabir A., Furton K. G., Fabric phase sorptive extractors, United States Patents 9557252, 31, January 2017
- 735 59. Samanidou V., Kaltzi I., Kabir A., Furton K.G. Simplifying sample preparation using fabric phase sorptive extraction technique
736 for the determination of benzodiazepines in blood serum by high-performance liquid chromatography *Biomed. Chromatogr.*
737 **2016**, 30, 829-836
- 738 60. Tartaglia, A.; Locatelli, M.; Kabir, A.; Furton, K.G.; Macerola, D.; Sperandio, E. Piccolantonio, S.; Ulusoy, H.I.; Maroni, F.; Bruni,
739 P.; Croce, F.; Samanidou, V.F. Comparison between Exhaustive and Equilibrium Extraction Using Different SPE Sorbents and
740 Sol-Gel Carbowax 20M Coated FPSE Media. *Molecules* **2019**, 24, 382.

- 741 61. Tartaglia, A., Covone, S., Rosato, E., Bonelli, M., Savini, F., Furton, K. G., Gazioglu I., D'Ovidio C., Kabir A., Locatelli, M. Fabric
742 phase sorptive extraction (FPSE) as an efficient sample preparation platform for the extraction of antidepressant drugs from
743 biological fluids. *Adv. Sample Prep.*, **2022** 3, 1-8.
- 744 62. Gazioglu, I., Tekkeli, S. E. K., Tartaglia, A., Aslan, C., Locatelli, M., Kabir, A. Simultaneous determination of febuxostat and
745 montelukast in human plasma using fabric phase sorptive extraction and high-performance liquid chromatog-
746 raphy-fluorimetric detection. *J. Chromatogr B*, **2022** 1188, 1-8.
- 747 63. Tiris G., Gazioglu I., Furton K.G., Kabir A., Locatelli M. Fabric phase sorptive extraction combined with high performance liq-
748 uid chromatography for the determination of favipiravir in human plasma and breast milk, *J. Pharm. Biomed. Anal*, **2023**, 223,
749 115131.
- 750 64. Locatelli M., Tartaglia A., Ulusoy H.I., Ulusoy S., Savini F., Rossi S., Santavenere F., Merone G.M., Bassotti E., D'Ovidio C.,
751 Rosato E., Furton K.G. Fabric-Phase sorptive membrane array as a noninvasive in vivo sampling device for human exposure to
752 different compounds *Anal. Chem.* **2021**, 93 (4), 1957-1961
- 753 65. Tartaglia, A., Kabir, A., Ulusoy, S., Sperandio, E., Piccolantonio, S., Ulusoy, H. I., Furton K.G. Locatelli, M. FPSE-HPLC-PDA
754 analysis of seven paraben residues in human whole blood, plasma, and urine. *J. Chromatogr B*, **2019**, 1125, 10.
- 755 66. Locatelli, M., Furton, K. G., Tartaglia, A., Sperandio, E., Ulusoy, H. I., Kabir, A. An FPSE-HPLC-PDA method for rapid deter-
756 mination of solar UV filters in human whole blood, plasma, and urine. *J. Chromatogr B*, **2019**, 1118, 40-50.
- 757 67. Sidiropoulou G., Kabir A., Furton K.G., Kika F.S., Fytianos K., Tzanavaras P.D., Zacharis C.K. Combination of fabric phase
758 sorptive extraction with UHPLC-ESI-MS/MS for the determination of adamantane analogues in human urine, *Microchem. J.*,
759 **2022**, 176, 107250.
- 760 68. Mazaraki K., Kabir A., Furton K.G., Fytianos K., Samanidou V.F., Zacharis C.K. Fast fabric phase sorptive extraction of selected
761 α -blockers from human serum and urine followed by UHPLC-ESI-MS/MS analysis, *J. Pharm. Biomed. Anal*, **2021**, 199, 114053.
- 762 69. Locatelli M., Covone S., Rosato E., Bonelli M., Savini F., Furton K.G., Gazioglu I., D'Ovidio C., Kabir A., Tartaglia A. Analysis of
763 seven selected antidepressant drugs in post-mortem samples using fabric phase sorptive extraction followed by high perfor-
764 mance liquid chromatography-photodiode array detection, *Forensic Chem.*, **2022**, 31, 100460.